| 因素 | 例数 | 3年总 生存率(%) | Х2值 | P值 | 3年局控率(%) | Х2值 | P值 | 3年无远处转移 生存率(%) | Х2值 | P值 |
| 性别 |
|
|
|
|
|
|
|
|
|
|
| 男 | 94 | 50.9 | 0.060 | 0.806 | 63.1 | 0.100 | 0.752 | 29.4 | 0.965 | 0.326 |
| 女 | 62 | 55.0 |
|
| 75.0 |
|
| 42.0 |
|
|
| 年龄 |
|
|
|
|
|
|
|
|
|
|
| ≤58岁 | 79 | 64.8 | 3.209 | 0.073 | 63.2 | 0.908 | 0.341 | 25.6 | 0.129 | 0.719 |
| >58岁 | 77 | 58.0 |
|
| 61.1 |
|
| 42.0 |
|
|
| T分期 |
|
|
|
|
|
|
|
|
|
|
| T1-3 | 57 | 67.9 | 8.879 | 0.012 | 94.3 | 6.641 | 0.036 | 35.2 | 0.369 | 0.832 |
| T4 | 97 | 40.0 |
|
| 37.5 |
|
| 33.0 |
|
|
| N分期 |
|
|
|
|
|
|
|
|
|
|
| N0-1 | 51 | 77.6 | 11.365 | 0.001 | 88.6 | 5.972 | 0.015 | 37.2 | 0.000 | 0.995 |
| N2-3 | 105 | 40.0 |
|
| 42.0 |
|
| 31.0 |
|
|
| 术后分期AJCC |
|
|
|
|
|
|
|
|
|
|
| I~II期 | 39 | 83.3 | 15.216 | 0.000 | 92.2 | 6.941 | 0.031 | 43.0 | 0.403 | 0.817 |
| III~IV期 | 115 | 54.0 |
|
| 40.0 |
|
| 37.0 |
|
|
| 病变部位 |
|
|
|
|
|
|
|
|
|
|
| 贲门 | 29 | 57.0 | 3.905 | 0.272 | 78.5 | 2.777 | 0.427 | 31.5 | 1.135 | 0.769 |
| 胃体 | 64 | 56.7 |
|
| 85.4 |
|
| 36.5 |
|
|
| 胃窦 | 55 | 50.0 |
|
| 47.5 |
|
| 31.5 |
|
|
| 病理类型 |
|
|
|
|
|
|
|
|
|
|
| 印戒细胞 | 35 | 57.2 | 0.430 | 0.512 | 50.7 | 0.598 | 0.439 | 31.0 | 1.178 | 0.278 |
| 非印戒细胞 | 121 | 50.0 |
|
| 70.0 |
|
| 35.0 |
|
|
| 解剖淋巴结总数 |
|
|
|
|
|
|
|
|
|
|
| ≤19枚 | 83 | 67.5 | 5.308 | 0.070 | 73.9 | 1.631 | 0.442 | 37.0 | 4.357 | 0.113 |
| >19枚 | 67 | 57.5 |
|
| 58.0 |
|
| 25.0 |
|
|
| 淋巴管 |
|
|
|
|
|
|
|
|
|
|
| 癌浸润 | 71 | 58.0 | 0.564 | 0.453 | 50.0 | 1.905 | 0.168 | 20.0 | 4.399 | 0.036 |
| 否 | 85 | 60.0 |
|
| 79.1 |
|
| 47.3 |
|
|
| 血管 |
|
|
|
|
|
|
|
|
|
|
| 癌浸润 | 67 | 56.0 | 1.515 | 0.218 | 50.0 | 1.222 | 0.269 | 25.0 | 2.896 | 0.089 |
| 否 | 89 | 60.9 |
|
| 78.6 |
|
| 43.7 |
|
|
| 神经 |
|
|
|
|
|
|
|
|
|
|
| 癌浸润 | 75 | 56.0 | 0.040 | 0.842 | 62.0 | 0.955 | 0.329 | 28.0 | 1.561 | 0.212 |
| 否 | 81 | 54.8 |
|
| 72.0 |
|
| 43.6 |
|
|
| 化疗方式 |
|
|
|
|
|
|
|
|
|
|
| 两药方案 | 64 | 45.4 | 11.211 | 0.047 | 60.4 | 9.500 | 0.091 | 46.6 | 6.679 | 0.246 |
| 三药方案 | 66 | 65.0 |
|
| 80.0 |
|
| 28.0 |
|
|